Simultaneous blastic plasmacytoid dendritic cell neoplasm and myelofibrosis: A case report.

Oncol Lett

Department of Hematology, Hebei General Hospital, Shijiazhuang, Hebei 050000, P.R. China.

Published: May 2024

AI Article Synopsis

  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive cancer often linked to other blood disorders, specifically myelofibrosis (MF) in this case.
  • A 70-year-old male presented with a large purplish-red rash and was diagnosed with BPDCN through biopsy and genetic tests.
  • Despite receiving one cycle of chemoimmunotherapy, the patient's condition worsened, resulting in an infection and ultimately his death, highlighting the severe prognosis and the need for increased awareness of BPDCN among medical professionals.

Article Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare and aggressive tumor with an unknown pathogenesis. Myelofibrosis (MF) is a type of myeloproliferative neoplasm. MF can be secondary to several hematological malignancies, including chronic myeloid leukemia, myelodysplastic syndrome and hairy cell leukemia. In the present report, a rare case of BPDCN secondary to MF is described. A 70-year-old male patient developed a large purplish-red rash with recurrent symptoms. BPDCN was confirmed by immunohistochemistry of a biopsy specimen and flow cytometry of bone marrow cells. Bone marrow histopathology revealed MF. Next-generation sequencing of peripheral blood revealed mutations in the Tet methylcytosine dioxygenase 2 and NRAS proto-oncogene GTPase genes. The patient underwent one cycle of chemoimmunotherapy, but the condition progressed, an infection developed and the patient eventually died. The present case suggests that BPDCN can occur in conjunction with MF and that the prognosis of such patients is poor. Pathological examination and genetic testing aided in the diagnosis and treatment. This case emphasizes the need to raise awareness of BPDCN among clinicians and to be alert to the potential for fatal infection in patients with BPDCN combined with MF following myelosuppression triggered during chemotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10996017PMC
http://dx.doi.org/10.3892/ol.2024.14354DOI Listing

Publication Analysis

Top Keywords

blastic plasmacytoid
8
plasmacytoid dendritic
8
dendritic cell
8
cell neoplasm
8
bone marrow
8
bpdcn
6
simultaneous blastic
4
neoplasm myelofibrosis
4
case
4
myelofibrosis case
4

Similar Publications

Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available. Lymphoma-like regimens with or without autologous or allogenic transplantation were the cornerstone of most therapeutic concepts.

View Article and Find Full Text PDF

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive orphan hematopoietic malignancy characterized by cutaneous and systemic hematologic involvement. BPDCN is frequently misidentified, but early, accurate diagnosis is critical to extending patient survival using tagraxofusp, a first-in-class CD123-targeted therapy, and increasing their chances of receiving a potentially curative stem cell transplantation. Cases of BPDCN in countries of the Gulf Cooperation Council are lower than the extrapolated incidence from other geographic locations due to lack of awareness of key diagnostic features, lack of consensus on the minimal phenotype for diagnosis, and lack of local immunohistochemistry testing facilities, contributing to underdiagnosis in this region.

View Article and Find Full Text PDF

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare and aggressive hematologic malignancy, arising from plasmacytoid dendritic cells (pDCs). BPDCN frequently has, at least initially, exclusively cutaneous presentation. We present a 45-year-old woman with a 3-month history of rapidly evolving violaceous patches, infiltrated plaques, and bruise-like tumefactions, disseminated on her face and upper trunk.

View Article and Find Full Text PDF

Research Progress in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao

December 2024

Department of Hematology, Hebei General Hospital,Shijiazhuang 050051,China.

Blastic plasmacytoid dendritic cell neoplasm(BPDCN)is an extremely rare invasive tumor with poor prognosis.The common clinical manifestations of BPDCN include skin injury,bone marrow involvement,and tumor cell spread.BPDCN is often misdiagnosed as other diseases and its diagnosis often requires a combination of clinical manifestations,imaging,histology,and immunophenotyping.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!